Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTA-TOC PET/CT Imaging in Neuroendocrine Tumors
NCT03001349Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2017
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium Ga 68-edotreotide in Neuroendocrine Neoplasm (NEN), meningioma, Multiple endocrine neoplasia type 1 (MEN1) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 30 days. Started May 2017; status: terminated.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
Neuroendocrine Neoplasm (NEN)meningiomaMultiple endocrine neoplasia type 1 (MEN1)von Hippel-Lindau syndrome (VHL)
Beyond the preview
Go deeper on NCT03001349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001349.